Glioblastoma multiforme: a propósito, un reporte de caso
Resumen
El glioblastoma multiforme (gbm) es un astrocitoma grado iv, siendo el tumor maligno más prevalente en el adulto, con un pronóstico muy malo desde su descubrimiento, entre 12 y 15 meses. La lesión puede ser primaria o secundaria, pero aún no se detalla exactamente qué permite su aparición debido a su perfil génico heterogéneo. Su diagnóstico se realiza por medio de imágenes, especialmente, los hallazgos clínicos, pero su confirmación se da a través de la biopsia al realizar la extracción quirúrgica. El reporte de caso muestra el deterioro neurológico que sufre el paciente de 58 años sin antecedentes de importancia y cómo este involuciona hasta fallecer; durante este
proceso se detalla el acompañamiento quirúrgico y farmacológico hasta la fecha en Colombia. No obstante, también hay nuevos avances en el desarrollo de terapias inmunológicas y farmacológicas ligadas a la nanotecnología que podrían aumentar la esperanza de vida.
Referencias bibliográficas
1. Czarnywojtek A, Borowska M, Dyrka K, Van Gool S, Sawicka-Gutaj N, Moskal J, et al. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques. Pharmacology. 2023;108(5):423-431. https://doi.org/10.1159/000531319
2. Khabibov M, Garifullin A, Boumber Y, Khaddour K, Fernandez M, Khamitov F, et al. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review). Int J Oncol. 2022 abr 19;60(6):69. https://doi.org/10.3892/ijo.2022.5359
3. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro Oncol. 2013 nov 1;15(suppl 2):ii1-56. https://doi.org/10.1093/neuonc/not151
4. Aldoghachi AF, Breyne K, Ling KH, Cheah PS. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. Neuroscience. 2022 may;491:240-270. https://doi.org/10.1016/j.neuroscience.2022.03.030
5. Pour ME, Moghadam SG, Shirkhani P, Sahebkar A, Mosaffa F. Therapeutic cell-based vaccines for glioblastoma multiforme. Medical Oncology. 2023 nov 12;40(12):354. https://doi.org/10.1007/s12032-023-02220-5
6. Vitovcova B, Skarkova V, Rudolf K, Rudolf E. Biology of Glioblastoma Multiforme — Exploration of Mitotic Catastrophe as a Potential Treatment Modality. Int J Mol Sci. 2020 jul 27;21(15):5324. https://doi.org/10.3390/ijms21155324
7. Yoshikawa MH, Rabelo NN, Telles JPM, Figueiredo EG. Modifiable risk factors for glioblastoma: a systematic review and meta-analysis. Neurosurg Rev. 2023 jun 20;46(1):143. https://doi.org/10.1007/s10143-023-02051-y
8. Ramaiah MJ, Kumar KR. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme. Mol Biol Rep. 2021 may 16;48(5):4813-4835. https://doi.org/10.1007/s11033-021-06462-2
9. Cortes Ballen AI, Amosu M, Ravinder S, Chan J, Derin E, Slika H, et al. Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets. Cells. 2024 sep 19;13(18). https://doi.org/10.3390/cells13181574
10. Drake LR, Hillmer AT, Cai Z. Approaches to PET Imaging of Glioblastoma. Molecules. 2020 ene 28;25(3):568. https://doi.org/10.3390/molecules25030568
11. Schäfer KC, Dénes J, Albrecht K, Szaniszló T, Balogh J, Skoumal R, et al. In vivo, in situ tissue analysis using rapid evaporative ionization mass spectrometry. Angewandte Chemie - International Edition. 2009;48(44). https://doi.org/10.1002/anie.200902546
12. Ma J, Li T, Chen H, Wang C, Wang H, Li Q. Lipidomic analysis and diagnosis of glioblastoma multiforme with rapid evaporative ionization mass spectrometry. Electrophoresis. 2021 oct 29;42(19):1965-1973. https://doi.org/10.1002/elps.202100130
13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 2005;352(10). https://doi.org/10.1056/nejmoa043330
14. Nozhat Z, Heydarzadeh S, Shahriari-Khalaji M, Wang S, Iqbal MZ, Kong X. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery. Biomater Sci. 2023;11(12):4094-4131. https://doi.org/10.1039/d2bm01996e
15. Wang H, Zhou H, Xu J, Lu Y, Ji X, Yao Y, et al. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Lett. 2021 ene;496:134-143. https://doi.org/10.1016/j.canlet.2020.09.028
16. Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current Immunotherapies for Glioblastoma Multiforme. Front Immunol. 2021 mar 9;11. https://doi.org/10.3389/fimmu.2020.603911
17. Jezierzański M, Nafalska N, Stopyra M, Furgoł T, Miciak M, Kabut J, et al. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme — A Literature Review and Clinical Outcomes. Current Oncology. 2024 jul 12;31(7):3994-4002. https://doi.org/10.3390/curroncol31070296
18. Abadi B, Ahmadi-Zeidabadi M, Dini L, Vergallo C. Current status and challenges of stem cell-based therapy for the treating of glioblastoma multiforme. Stem cell-based therapy treating glioblastoma multiforme. Hematol Oncol Stem Cell Ther. 2021 ene;14(1):1-15. https://doi.org/10.1016/j.hemonc.2020.08.001
19. Kumari S, Gupta R, Ambasta RK, Kumar P. Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy. Biochimica et Biophysica Acta (BBA). Reviews on Cancer. 2023 jul;1878(4):188913. https://doi.org/10.1016/j.bbcan.2023.188913
20. Guo QL, Dai XL, Yin MY, Cheng HW, Qian HS, Wang H, et al. Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives. Mil Med Res. 2022 jun 9;9(1):26. https://doi.org/10.1186/s40779-022-00386-z
21. Hsu JF, Chu SM, Liao CC, Wang CJ, Wang YS, Lai MY, et al. Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update. Cancers (Basel). 2021 ene 7;13(2):195. https://doi.org/10.3390/cancers13020195
22. Prattipati V. Editorial Comment: MRI and PET for Immunotherapy Response Assessment in Glioblastoma Multiforme. American Journal of Roentgenology. 2022 abr;218(4):597. https://doi.org/10.2214/ajr.21.26584
23. Reilly JM, Gundersen AI, Silver JK, Tan CO, Knowlton SE. A Comparison of Functional Outcomes between Patients Admitted to Inpatient Rehabilitation after Initial Diagnosis Versus Recurrence of Glioblastoma Multiforme. PM&R. 2020 oct 12;12(10):975-983. https://doi.org/10.1002/pmrj.12379
24. Xu W, Han L, Zhu P, Cheng Y, Chen X. Development of a prognostic model for glioblastoma multiforme based on the expression levels of efferocytosis-related genes. Aging. 2023 dic 31;15(24):15578-15598. https://doi.org/10.18632/aging.205422
25. Zheng H, Yan T, Han Y, Wang Q, Zhang G, Zhang L, et al. Nomograms for prognostic risk assessment in glioblastoma multiforme: Applications and limitations. Clin Genet. 2022 nov;102(5):359-368. https://doi.org/10.1111/cge.14200
